Kosta Steliou

Kosta Steliou

Auto-generated profile, based on publicly available information

Kosta Steliou

Boston University, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in BioResearch Open Access
Verified
Journal Article
Open access
KSKosta Steliou
Kosta Steliou
MBMichael S. Boosalis
Michael S. Boosalis
SPSusan P. Perrine
Susan P. Perrine
JSJosé Sangerman
José Sangerman
DFDouglas V. Faller
Douglas V. Faller
In addition to being a part of the metabolic fatty acid fuel cycle, butyrate is also capable of inducing growth arrest in a variety of normal cell types and senescence-like phenotypes in gynecological cancer cells, inhibiting DNA synthesis and cell growth in colonic tumor cell lines, suppressing hTERT mRNA expression and telomerase activity in human prostate cancer cells, and inducing stem cell differentiation and apoptosis by DNA fragmentation. It regulates gene expression by inhibiting histone deacetylases (HDACs), enhances memory recovery and formation in mice, stimulates neurogenesis in the ischemic brain, promotes osteoblast formation, selectively blocks cell replication in transformed cells (compared to healthy cells), and can prevent and treat diet-induced obesity and insulin resistance in mouse models of obesity, as well as stimulate fetal hemoglobin expression in individuals with hematologic diseases such as the thalassemias and sickle-cell disease, in addition to a multitude of other biochemical effects in vivo. However, efforts to exploit the potential of butyrate in the clinical treatment of cancer and other medical disorders are thwarted by its poor pharmacological properties (short half-life and first-pass hepatic clearance) and the multigram doses needed to achieve therapeutic concentrations in vivo. Herein, we review some of the methods used to overcome these difficulties with an emphasis on HDAC inhibition.

1 December 2010 in Rejuvenation Research
Verified
Journal Article
Closed access
KPKodeeswaran Parameshwaran
Kodeeswaran Parameshwaran
MIMichael H. Irwin
Michael H. Irwin
KSKosta Steliou
Kosta Steliou
Carl A. PinkertCarl A. Pinkert
Carl A. Pinkert
Accumulating evidence suggests that mitochondrial dysfunction and oxidative stress play major roles in aging. Chronic administration of D -galactose has been reported to cause deterioration of cognitive and motor skills that are similar to symptoms of aging and, therefore, is regarded as a model of accelerated aging. Because enhancing endogenous antioxidants is now widely regarded as an attractive therapy for conditions associated with mitochondrial oxidative stress, in the present study the effects of α-lipoic acid, L -carnitine, and PMX-500F on D -galactose treated mice were tested. Female mice were injected with (100 mg/kg) D -(+)-galactose for 6 weeks and some groups were treated with a daily dose of α-lipoic acid (5 mg/kg), L -carnitine (3.9 mg/kg), PMX-500F (11.9 mg/kg), or the vehicle (0.1 M Tris, pH 7.4). Control mice were treated with physiological saline. An accelerating Rota-Rod, open field test, and Y-maze test were performed, and serum lactate concentrations were analyzed. These analyses did not identify impairment in motor coordination, open-field activity, or spatial memory ( p > 0.05). Similarly, serum lactate concentrations in D -galactose-treated mice were not elevated when compared to controls ( p > 0.05). Treatment with the antioxidant compounds at the given concentrations did not result in any changes in the behavioral parameters tested. In conclusion, results of this study illustrate that chronic, short-term D -galactose treatment may not represent a suitable model for inducing readily detectable age-related neurobehavioral symptoms in mice.

1 November 2016 in BioResearch Open Access
Verified
Journal Article
Open access
WMWalter H. Moos
Walter H. Moos
DFDouglas V. Faller
Douglas V. Faller
DHDavid N. Harpp
David N. Harpp
IKIphigenia Kanara
Iphigenia Kanara
JPJulie Pernokas
Julie Pernokas
KSKosta Steliou
Kosta Steliou
In the past century, noncommunicable diseases have surpassed infectious diseases as the principal cause of sickness and death, worldwide. Trillions of commensal microbes live in and on our body, and constitute the human microbiome. The vast majority of these microorganisms are maternally derived and live in the gut, where they perform functions essential to our health and survival, including: digesting food, activating certain drugs, producing short-chain fatty acids (which help to modulate gene expression by inhibiting the deacetylation of histone proteins), generating anti-inflammatory substances, and playing a fundamental role in the induction, training, and function of our immune system. Among the many roles the microbiome ultimately plays, it mitigates against untoward effects from our exposure to the environment by forming a biotic shield between us and the outside world. The importance of physical activity coupled with a balanced and healthy diet in the maintenance of our well-being has been recognized since antiquity. However, it is only recently that characterization of the host–microbiome intermetabolic and crosstalk pathways has come to the forefront in studying therapeutic design. As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota–host maladaptation), although this has yet to be proven. However, the development and use of small molecule drugs have a long and successful history in the clinic, with small molecule histone deacetylase inhibitors representing one relevant example already approved to treat cancer and other disorders. Moreover, preclinical research suggests that epigenetic treatment of neurological conditions holds significant promise. With the mouth being an extension of the digestive tract, it presents a readily accessible diagnostic site for the early detection of potential unhealthy pathogens resident in the gut. Taken together, the data outlined herein provide an encouraging roadmap toward important new medicines and companion diagnostic platforms in a wide range of therapeutic indications.

1 February 1978 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DHDavid N. Harpp
David N. Harpp
KSKosta Steliou
Kosta Steliou
TCT. H. Chan
T. H. Chan

1 November 1983 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KSKosta Steliou
Kosta Steliou
MPMarc Andre Poupart
Marc Andre Poupart

1 February 1979 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ASAlan Shaver
Alan Shaver
PFPaul J. Fitzpatrick
Paul J. Fitzpatrick
KSKosta Steliou
Kosta Steliou
IBIan S. Butler
Ian S. Butler